US 12,247,026 B2
Heterocyclic compounds as immunomodulators
Liangxing Wu, Wilmington, DE (US); Jingwei Li, Westfield, NJ (US); and Wenqing Yao, Chadds Ford, PA (US)
Assigned to Incyte Corporation, Wilmington, DE (US)
Filed by Incyte Corporation, Wilmington, DE (US)
Filed on Aug. 18, 2021, as Appl. No. 17/405,204.
Application 17/405,204 is a continuation of application No. 16/856,678, filed on Apr. 23, 2020, granted, now 11,124,511.
Application 16/856,678 is a continuation of application No. 16/369,654, filed on Mar. 29, 2019, granted, now 10,669,271, issued on Jun. 2, 2020.
Claims priority of provisional application 62/687,964, filed on Jun. 21, 2018.
Claims priority of provisional application 62/650,821, filed on Mar. 30, 2018.
Prior Publication US 2021/0380584 A1, Dec. 9, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 471/04 (2006.01); A61K 31/519 (2006.01); A61P 35/00 (2006.01); A61P 37/04 (2006.01); C07D 413/14 (2006.01)
CPC C07D 471/04 (2013.01) [A61P 37/04 (2018.01); C07D 413/14 (2013.01)] 122 Claims
 
1. A method of treating cancer, wherein the cancer is selected from the group consisting of breast cancer, head and neck cancer, colorectal cancer, cervical cancer, endometrial cancer, gastric cancer, esophageal cancer, cancers with high microsatellite instability (MSThigh), biliary tract cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, lung cancer, cutaneous squamous cell carcinoma, hepatic cancer, melanoma, cancer of the bladder, cancer of the urethra, and renal cancer; said method comprising administering to a patient in need thereof a therapeutically effective amount of a compound selected from:
(R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid,
(R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid,
(R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-3-methylpyrrolidine-3-carboxylic acid,
(R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, and
(S)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid,
or a pharmaceutically acceptable salt thereof.